Twist Bioscience (TWST) Rallies As Growth Narrative Tests Whether The Stock Is Already Pricey

Twist Bioscience (TWST) has drawn fresh attention after recent trading left the stock at US$188.67, with moves over the past month and past 3 months sharply outpacing its shorter term performance.

For context, Twist Bioscience now trades at US$188.67 after a 30 day share price return of 44.02% and a 90 day gain of 90.11%. The total shareholder return over the past year is about 6x and over the past three years is close to 10x, which points to strong momentum and a material reset in how the market is pricing both its growth potential and its risks.

Scan other high-momentum biotech stories alongside Twist Bioscience by filtering for 19 high quality undiscovered gems that have already started to move but still fly under most investors' radar.

Bulls point to Twist Bioscience’s rapid share price move and revenue expansion, while bears focus on continued losses and a premium to analyst targets. Which side does the valuation math lean toward next?

Most Popular Narrative: 72% Overvalued

Twist Bioscience last traded at $188.67, while the most followed narrative anchors fair value at $109.58, so the gap between share price and modeled worth is wide and hard to ignore.

Diversification across multiple end markets and geographies, coupled with strong underlying industry trends like AI-driven drug discovery and global genomics market expansion, provides resilience against market cycles and supports steady, long-term revenue and profit growth.

See why 23 investors see Twist Bioscience as 72% overvalued.

Result: Fair Value of $109.58 (OVERVALUED)

Still, Twist Bioscience carries real risk if ongoing losses persist and customer concentration in NGS wobbles, since either factor could quickly challenge today’s rich narrative.

Find out about the key risks to this Twist Bioscience narrative.

Another View: Twist Bioscience Through The DCF Lens

There is a sharp contrast when switching to the Simply Wall St DCF model. On that framework, Twist Bioscience at $188.67 is trading about 13% below an estimated future cash flow value of $216.26, which points to undervaluation rather than excess optimism. Which story do you think better fits your own assumptions?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Twist Bioscience for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 31 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of optimism and worry around Twist Bioscience feels conflicted, treat it as your cue to move quickly and review the full picture yourself. To weigh the upside against the downside with one clear snapshot, start by checking the 2 key rewards and 3 important warning signs.

Looking for more ideas beyond Twist Bioscience?

Do not stop your research with Twist Bioscience when there are plenty of other opportunities that might fit your risk tolerance and return expectations.

• Target steady compounders by reviewing companies in the 31 high quality undervalued stocks that combine quality fundamentals with prices that sit below their assessed worth.
• Prioritise capital strength by scanning the list of solid balance sheet and fundamentals (26 results) where resilient financial positions can help cushion tougher market conditions.
• Reduce sleepless nights by checking the 31 resilient stocks with low risk scores that focuses on businesses with more stable profiles than the typical high-volatility play.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com